Table 4.

Impact of Toolkit on Knowledge and Confidence among Toolkit Users and Non-Users

Knowledge
	Users (Used Toolkit)		Non-Users (Did Not Used Toolkit)		F for Time	F for Time ^* Use
	n	Mean±SD	n	Mean±SD	F for Time	F for Time ^* Use
Nature of ADHD
Baseline	42	3.1±0.8	26	2.9±0.5	24.67^*	0.20
Midpoint		3.1±0.8		3.0±0.8	24.67^*	0.20
Final		3.6±0.7		3.5±0.7
Effects of ADHD on quality of life and risk associated with untreated ADHD
Baseline	43	3.2±0.9	25	3.0±0.8	16.52^*	0.92
Midpoint		3.2±0.9		3.2±0.7	16.52^*	0.92
Final		3.7±0.7		3.5±0.7
ADHD diagnostic process in adults
Baseline	43	2.7±0.8	24	2.6±0.7	24.00^*	1.13
Midpoint		3.0±0.9		2.8±0.6	24.00^*	1.13
Final		3.4±0.8		3.2±0.8
Management of ADHD in adults
Baseline	43	2.9±0.8	23	2.8±0.9	10.73^*	1.65
Midpoint		3.3±0.8		2.9±0.6	10.73^*	1.65
Final		3.5±0.8		3.2±0.8
Management of ADHD in young adults
Baseline	42	3.1±0.8	25	3.0±0.7	20.20^*	1.32
Midpoint		3.4±0.7		3.0±0.8
Final		3.7±0.7		3.4±0.8
Management of ADHD in women
Baseline	43	3.0±0.8	25	2.9±0.6	15.02^*	1.03
Midpoint		3.3±0.8		3.0±0.8	15.02^*
Final		3.6±0.7		3.4±0.8
Management of ADHD in patients with co-morbid conditions
Baseline	42	2.7±0.7	26	2.8±0.7	7.98^*	3.87^*
Midpoint		3.2±0.7		2.7±0.6
Final		3.4±0.7		2.9±0.7
Management of ADHD in older adults
Baseline	43	2.5±0.6	26	2.4±0.8	24.60^*	0.97
Midpoint		3.0±0.8		2.7±0.7
Final		3.2±0.6		3.0±0.7
Monitoring for treatment effects, side effects and outcomes
Baseline	41	3.1±0.8	26	3.1±0.7	8.15^*	5.08^*
Midpoint		3.6±0.8		3.0±0.7
Final		3.5±0.7		3.4±0.9
Patient safety with the use of stimulants in adults
Baseline	43	3.1±0.7	26	2.9±0.9	12.46^*	0.15
Midpoint		3.3±0.8		3.0±0.7
Final		3.6±0.7		3.4±0.8
Prevention of non-medical use of stimulants in adults
Baseline	43	2.8±0.8	26	2.9±0.8	11.08^*	2.49
Midpoint		3.1±0.7		2.8±0.9
Final		3.5±0.7		3.2±0.9
Understanding of potential for abuse of immediate-release stimulants
Baseline	42	3.1±0.8	24	3.2±0.8	9.44^*	2.03
Midpoint		3.4±0.9		3.1±0.8
Final		3.8±0.9		3.4±0.9
Federal prescribing requirements for stimulants as controlled substance
Baseline	42	3.0±0.9	26	3.0±1.0	13.61^*	1.54
Midpoint		3.5±0.9		3.2±0.9
Final		3.7±0.8		3.5±0.7
State prescribing requirements for stimulants as controlled substance
Baseline	42	3.1±1.0	26	3.0±1.1	15.17^*	0.67
Midpoint		3.4±0.9		3.1±0.9
Final		3.6±0.8		3.6±0.6
Existing resources for patients and clinicians about adult ADHD
Baseline	42	2.5±0.8	26	2.6±0.8	28.09^*	3.50^*
Midpoint		3.3±0.9		2.9±0.7
Final		3.4±0.9		3.3±0.8
Communication with patients about any aspect of ADHD including the nature of ADHD, the medication treatment options, the non-pharmacological treatment options, patient's role in ADHD management, locating support services, training options and self-education resources, etc.
Baseline	43	3.0±0.8	25	2.7±2.5	20.41^*	0.10
Midpoint		3.1±0.8		2.8±0.6
Final		3.6±0.8		3.3±0.8

Confidence
	Used Toolkit		Did Not Used Toolkit		F for Time	F for Time ^* Use
	n	Mean±SD	n	Mean±SD	F for Time	F for Time ^* Use
Diagnosing and treating ADHD in adults
Baseline	45	2.6±0.9	26	2.4±0.9	25.99^*	1.33
Midpoint		3.3±0.8		2.8±1.0
Final		3.3±1.0		3.2±0.7
Recognizing and screening for ADHD in adults
Baseline	44	2.4±0.9	26	2.4±1.1	32.20^*	1.76
Midpoint		3.2±0.9		2.8±0.9
Final		3.4±0.9		3.0±0.7
Making a diagnosis in patients who do not display classic childhood symptoms of hyperactivity and impulsivity
Baseline	45	2.0±1.0	26	1.8±1.0	20.49^*	0.58
Midpoint		2.8±1.0		2.4±1.0
Final		3.0±1.0		2.5±1.0
Full evaluation of ADHD symptoms and coexisting disorders
Baseline	44	2.3±1.0	26	2.2±1.0	24.99^*	2.07
Midpoint		3.0±1.0		2.5±0.9
Final		3.2±1.1		2.9±0.9
Use of rating scales as an initial screening step
Baseline	43	2.6±1.0	26	2.4±1.2	11.96^*	0.14
Midpoint		3.1±0.9		2.7±1.3
Final		3.3±1.1		3.0±1.0
Mental health interview techniques and life history interview
Baseline	44	2.8±0.9	26	3.0±1.0	5.02^*	4.22^*
Midpoint		3.3±1.0		3.2±1.0
Final		3.5±0.9		3.0±0.8
Choosing treatment options for uncomplicated ADHD in adults
Baseline	44	2.8±1.0	26	2.7±1.2	22.21^*	0.97
Midpoint		3.5±0.8		3.2±1.1
Final		3.6±1.0		3.2±0.8
Choosing treatment options for ADHD with co-morbid mental health disorders
Baseline	44	2.5±0.9	26	2.2±0.9	11.28^*	5.39^*
Midpoint		3.1±0.9		2.4±0.8
Final		3.2±1.0		2.3±0.8
Choosing treatment options for ADHD with co-existing substance use disorder
Baseline	45	2.0±1.0	26	1.9±1.0	17.21^*	3.79^*
Midpoint		2.8±1.1		2.1±0.9
Final		3.0±1.0		2.3±1.0
Follow up care practices
Baseline	45	2.8±1.0	26	2.7±1.0	18.78^*	1.91
Midpoint		3.5±0.9		3.0±1.0
Final		3.5±0.9		3.0±0.9
Providing patient education related to any aspect of ADHD in adults
Baseline	45	2.6±1.0	26	2.4±1.0	28.61^*	2.41
Midpoint		3.4±1.0		2.8±0.8
Final		3.6±0.9		3.0±0.9
Identifying and managing patients at risk for stimulant misuse, abuse and diversion
Baseline	45	2.6±1.0	26	2.5±0.9	10.94^*	0.98
Midpoint		3.3±0.9		2.8±1.0
Final		3.2±1.0		2.9±1.0

ADHD, Attention Deficient Hyperactivity Disorder; SD, standard deviation.
↵* P value < 0.05.